drugset / Trial / NCT02214628
Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD
RandomizedSingle-groupOpen-labelTreatment
Summary
The objective is to evaluate the safety of intravitreal Fovista® (anti-PDGF BB) administered in combination with anti-VEGF therapy.
Timeline
- Start
- 2014-07
- Primary completion
- 2016-12
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PEGPLERANIB SODIUM | Aptamer | — | Intravitreal |
| Background | Aflibercept | Protein / enzyme biologic | — | — |
| Background | Bevacizumab | Monoclonal antibody | — | — |
| Background | Ranibizumab | Monoclonal antibody | — | — |